A Phase 3 interventional study of Bupivacaine liposome and Placebo in Dental Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-10.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.
Among the 54 studies in Toothache with a site in United States, this one is the 27th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2015, is one of 11 in phase 3, and was the 35th registered.
142 studies on the registry are indexed under Toothache; 28 are open to participants now.
Browse Toothache studies →6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 84 across 123 interventional studies indexed under Toothache.
Median enrollment 194 across the 50 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 1 study filed under Toothache — fewer than ten, so there is no comparison to draw.
4 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, placebo-controlled study in subjects scheduled to undergo elective bilateral third molar extraction under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiographic evidence.
Subjects will be screened within 30 days prior to surgery.
Randomized subjects will receive a dental nerve block with lidocaine 2% with epinephrine 1:100,000 before undergoing bilateral third molar extraction under local anesthesia. In addition to the lidocaine nerve block, the Investigator may choose to add topical benzocaine or intraoperative nitrous oxide.
At the end of surgery, and at least 20 minutes after the lidocaine administration, blinded study drug will be infiltrated to provide postsurgical analgesia. Subjects will be required to remain in the research facility for 96 hours after study drug administration.
Postsurgical efficacy, safety, and pharmacokinetic (PK) assessments will be conducted.
All subjects will return for a follow-up visits on Days 7 and 10. A phone call will be made to each subject on Day 30 for an adverse event (AE) assessment and to inquire as to whether the subject made any unscheduled phone calls or office visits related to pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
Drug: Bupivacaine liposome
10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
Drug: Placebo
Local administration
Also known as: EXPAREL
Local administration
Also known as: Normal saline
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours
AUC of NRS pain intensity scores through 48 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
Time frame: 0-48 hours
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours
AUC of NRS pain intensity scores through 24 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain) 0-24 hours
Time frame: 0-24 hours
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours
AUC of NRS pain intensity scores through 72 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
Time frame: 0-72 hours
Percentage of Opioid-free Subjects Through 24 Hours.
Percentage of opioid-free subjects through 24 hours.
Time frame: 0-24 hours
Percentage of Opioid-free Subjects Through 48 Hours.
Percentage of opioid-free subjects through 48 hours.
Time frame: 0-48 hours
Percentage of Opioid-free Subjects Through 72 Hours.
Percentage of opioid-free subjects through 72 hours.
Time frame: 0-72 hours
| Milestone | EXPAREL 133 mg | Placebo |
|---|---|---|
| Started | 107 | 59 |
| Completed | 97 | 57 |
| Not completed | 10 | 2 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Screen failure | 2 | 2 |
AUC of NRS pain intensity scores through 48 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
| units on NRS scale*hr | EXPAREL 133 mg | Placebo |
|---|---|---|
| Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours | 178.9 ± 10.30 | 181.6 ± 13.63 |
AUC of NRS pain intensity scores through 24 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain) 0-24 hours
| units on NRS scale*hr | EXPAREL 133 mg | Placebo |
|---|---|---|
| Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours | 102.4 ± 4.73 | 106.4 ± 6.26 |
AUC of NRS pain intensity scores through 72 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
| units on NRS scale*hr | EXPAREL 133 mg | Placebo |
|---|---|---|
| Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours | 241.5 ± 15.40 | 235.6 ± 20.38 |
Percentage of opioid-free subjects through 24 hours.
| Participants | EXPAREL 133 mg | Placebo |
|---|---|---|
| Percentage of Opioid-free Subjects Through 24 Hours. | 19 | 12 |
Percentage of opioid-free subjects through 48 hours.
| Participants | EXPAREL 133 mg | Placebo |
|---|---|---|
| Percentage of Opioid-free Subjects Through 48 Hours. | 19 | 12 |
Percentage of opioid-free subjects through 72 hours.
| Participants | EXPAREL 133 mg | Placebo |
|---|---|---|
| Percentage of Opioid-free Subjects Through 72 Hours. | 18 | 12 |
Collected over From screening to postsurgical day 29. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL 133 mg | 0/105 (0%) | 0/105 (0%) | 105/105 (100%) |
| Placebo | 0/57 (0%) | 0/57 (0%) | 57/57 (100%) |
| Event | EXPAREL 133 mg | Placebo |
|---|---|---|
| Hypoesthesia oralNervous system disorders | 104/105 | 57/57 |
| DysgeusiaNervous system disorders | 80/105 | 32/57 |
| NauseaGastrointestinal disorders | 32/105 | 16/57 |
| Muscle contractions involuntaryNervous system disorders | 16/105 | 12/57 |
| VomitingGastrointestinal disorders | 18/105 | 9/57 |
| HeadacheNervous system disorders | 6/105 | 9/57 |
| DizzinessNervous system disorders | 11/105 | 8/57 |
| Post procedural edemaInjury, poisoning and procedural complications | 10/105 | 7/57 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 8/105 | 4/57 |
| Upper respiratory tract infectionInfections and infestations | 4/105 | 2/57 |
Safety population included all participants who received study drug, with analysis by actual treatment received.
| Age, Continuous(years) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| Mean | 20.9 ± 3.81 | 20.9 ± 4.76 | 20.9 ± 4.15 |
| Sex: Female, Male(Participants) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| Female | 53 | 33 | 86 |
| Male | 52 | 24 | 76 |
| Ethnicity (NIH/OMB)(Participants) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 7 | 23 |
| Not Hispanic or Latino | 89 | 50 | 139 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 9 | 1 | 10 |
| White | 94 | 53 | 147 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| United States | 105 | 57 | 162 |
| Body Mass Index(kg/m2) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| Mean | 25.8 ± 6.87 | 24.5 ± 4.72 | 25.3 ± 6.21 |
| Impaction Scores(Participants) | EXPAREL 133 mg | Placebo | Total |
|---|---|---|---|
| 4 fully bony impacted teeth | 23 | 19 | 42 |
| 3 fully bony impacted teeth, 1 partially impacted | 14 | 7 | 21 |
| 3 fully bony impacted teeth | 1 | 3 | 4 |
| 2 fully bony impacted teeth, 2 partially impacted | 10 | 7 | 17 |
| 2 fully bony impacted teeth, 1 partially impacted | 9 | 2 | 11 |
| 2 fully bony impacted teeth | 3 | 6 | 9 |
| 1 fully bony impacted tooth, 3 partially impacted | 4 | 1 | 5 |
| 1 fully bony impacted tooth, 2 partially impacted | 7 | 3 | 10 |
| 1 fully bony impacted tooth, 1 partially impacted | 8 | 5 | 13 |
| 1 fully bony impacted tooth | 2 | 2 | 4 |
| 4 partially impacted teeth | 3 | 0 | 3 |
| 3 partially impacted teeth | 4 | 0 | 4 |
| 2 partially impacted teeth | 16 | 1 | 17 |
| 1 partially impacted tooth | 1 | 1 | 2 |
| No impactions | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2020, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine